Logo
Search
Sign Up

The Pulse Check

The Pulse Check

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Dec 19, 2025

•

11 min read

Biotech is the Most Mispriced Sector on the ASX (and the Three Stocks That Proved It)

Jason Segal
Jason Segal

The Pulse Check

Putting ASX Healthcare in the Hot Seat in 2026

Dec 18, 2025

•

6 min read

Putting ASX Healthcare in the Hot Seat in 2026

Jason Segal
Jason Segal

The Pulse Check

Same Result. Two Markets. Very Different Answers.

Dec 17, 2025

•

9 min read

Same Result. Two Markets. Very Different Answers.

Jason Segal
Jason Segal

The Pulse Check

The Holiday Trade I like to do once a Year

Dec 16, 2025

•

7 min read

The Holiday Trade I like to do once a Year

Jason Segal
Jason Segal

The Pulse Check

Trump floats new cannabis rules: Weeding out the good from the bad

Dec 15, 2025

•

11 min read

Trump floats new cannabis rules: Weeding out the good from the bad

Jason Segal
Jason Segal

The Pulse Check

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Dec 12, 2025

•

9 min read

$3.2 Billion Raised This Week in the US Biotech Markets... Australia Next?

Jason Segal
Jason Segal

The Pulse Check

+2

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Dec 11, 2025

•

9 min read

Immuron’s Clinical Trial Faceplant: Bad News... But Not a Company Killer

Jason Segal
Jason Segal

Imugene (ASX: IMU)

+1

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Dec 10, 2025

•

9 min read

Imugene’s Phase 3 Pathway Is Clear - Its Funding Path Isn’t

Jason Segal
Jason Segal

The Pulse Check

+1

Immutep drops a US$370M deal... at 6:54pm

Dec 9, 2025

•

7 min read

Immutep drops a US$370M deal... at 6:54pm

Jason Segal
Jason Segal

The Pulse Check

+3

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Dec 8, 2025

•

11 min read

A Tale of Two IPOs: Lessons From Saluda and Epiminder’s Tough Debuts

Jason Segal
Jason Segal

The Pulse Check

+1

Are AI-Predicted Clinical Trials the Future of Drug Development?

Dec 5, 2025

•

5 min read

Are AI-Predicted Clinical Trials the Future of Drug Development?

Jason Segal
Jason Segal

The Pulse Check

+1

The Moment Invion (IVX) Became “Investible” for me

Dec 4, 2025

•

7 min read

The Moment Invion (IVX) Became “Investible” for me

Jason Segal
Jason Segal

The Pulse Check

+1

The Hidden Signals Found in AGM Updates

Dec 3, 2025

•

7 min read

The Hidden Signals Found in AGM Updates

Jason Segal
Jason Segal

Visionflex Group (ASX:VFX)

+1

Inside the Visionflex Lazarus Story

Dec 2, 2025

•

6 min read

Inside the Visionflex Lazarus Story

Jason Segal
Jason Segal

The Pulse Check

+1

What happens when a biotech stock goes up on "no news"...

Dec 1, 2025

•

5 min read

What happens when a biotech stock goes up on "no news"...

Jason Segal
Jason Segal

The Pulse Check

Biotech green shoots emerge in Australia and the US

Nov 28, 2025

•

4 min read

Biotech green shoots emerge in Australia and the US

Jason Segal
Jason Segal

The Pulse Check

+1

What does a "leveraged" clinical trial bet look like

Nov 27, 2025

•

5 min read

What does a "leveraged" clinical trial bet look like

Jason Segal
Jason Segal

The Pulse Check

Paul Hopper voted out, PIQ gets Reimbursement, Ethics Approval for RAC

Nov 26, 2025

•

6 min read

Paul Hopper voted out, PIQ gets Reimbursement, Ethics Approval for RAC

Jason Segal
Jason Segal

The Pulse Check

Philips swings big at ASX listed minnows

Nov 25, 2025

•

4 min read

Philips swings big at ASX listed minnows

Jason Segal
Jason Segal

The Armchair Analyst

© 2025 The Armchair Analyst.

Report abuse

Privacy policy

Terms of use

Powered by beehiiv